Avant BrandsFRA:1BU 35 Net Margin % is -24.31% as of Feb. 2026. GuruFocus rates FRA:1BU with a GF Score™ of 35/100 and a GF Value™ of €0.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Avant Brands ranks worse than 83.68% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Avant Brands's Net Income for the
three
months ended in Feb. 2026 was €-2.13 Mil. Avant Brands's Revenue for the
three
months ended in Feb. 2026 was €8.76 Mil. Therefore, Avant Brands's net margin for the quarter that ended in Feb. 2026 was -24.31%.
The historical rank and industry rank for Avant Brands's Net Margin % or its related term are showing as below:
FRA:1BU'
s Net Margin % Range Over the Past 10 Years
Min: -18151.72 Med: -90.63 Max: -19.25
Current: -29.92
FRA:1BU's Net Margin % is ranked worse than 83.68% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:1BU: -29.92
Avant Brands (FRA:1BU) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Avant Brands Net Margin % Related Terms
Avant Brands Net Margin % Historical Data
* Premium members only.
The historical data trend for Avant Brands's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avant Brands's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avant Brands Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avant Brands's Net Margin % distribution charts can be found below:
* The bar in red indicates where Avant Brands's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avant Brands (FRA:1BU) has a Net Margin % of -24.31% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Avant Brands and its competitors. According to the industry distribution chart, Avant Brands ranks #800 out of 956 companies in the Drug Manufacturers industry, placing it in the top 83.7%.
Is Avant Brands' Net Margin % too high?
Avant Brands' current Net Margin % is -24.31%. Based on the distribution chart, Avant Brands ranks #800 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Avant Brands has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avant Brands' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avant Brands ranks #800 out of 956 companies for Net Margin %. This places Avant Brands in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Avant Brands and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avant Brands's current Net Margin % is -24.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avant Brands stock overvalued right now?
Based on GuruFocus' analysis, Avant Brands (FRA:1BU) is currently considered Possible Value Trap. The stock's GF Value™ is €0.74, compared to a current price of €0.33 — trading 54.9% below its estimated fair value. The current Net Margin % is -24.31%. Avant Brands' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Avant Brands (FRA:1BU), the current Net Margin % is -24.31% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avant Brands (FRA:1BU) Overvalued in 2026?
Based on GuruFocus' analysis, Avant Brands stock appears to be undervalued.
The current stock price of €0.33 is trading 54.9% below its estimated GF Value™ of €0.74.
GuruFocus considers Avant Brands to be Possible Value Trap.
Key valuation signals for FRA:1BU:
Net Margin %: -24.31%
GF Value™: €0.74 vs. price of €0.33 (54.9% below fair value)
No single metric tells the full story. See the FRA:1BU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avant Brands Inc operating in the cannabis industry, engages in the cultivation, production, marketing, and sale of cannabis products. Its product portfolio mainly consists of dried cannabis flower and related cannabis products, with the company managing the entire value chain from cultivation and harvesting to processing, packaging, and distribution, generating revenue upon delivery of products to customers. It operates in Canada.
35GF Score
Get the complete analysis for FRA:1BU
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BU has been successfully added to your 
